[1] Psaltis PJ, Zannettino AC, Worthley SG,et al.Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 2008;26(9):2201-2210.
[2] Przybyt E, Harmsen MC. Mesenchymal stem cells: promising for myocardial regeneration. Curr Stem Cell Res Ther. 2013; 8(4):270-277.
[3] Rossant J.Stem cells from the Mammalian blastocyst.Stem Cells. 2001;19(6):477-482.
[4] Pal R.Embryonic stem (ES) cell-derived cardiomyocytes: a good candidate for cell therapy applications.Cell Biol Int. 2009; 33(3):325-336.
[5] Hipp J, Atala A.Sources of stem cells for regenerative medicine.Stem Cell Rev. 2008;4(1):3-11.
[6] Williams AR, Hare JM.Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.Circ Res. 2011;109(8): 923-940.
[7] Yan XR,Yang YH,Liu W,et al.Differentiation of neuron-like cells from mouse parthenogenetic embryonic stem cells. Neural Regen Res. 2013; 8(4): 293-300.
[8] Gnecchi M, Danieli P, Cervio E.Mesenchymal stem cell therapy for heart disease.Vascul Pharmacol. 2012; 57(1): 48-55.
[9] 郭志林,王新庄,王木,等.影响昆明小鼠和BALB/C小鼠胚胎干细胞分离、克隆、传代的若干因素[J].中国兽医学报,2006, 26(4): 448-450.
[10] 李恩书,彭新荣,钱其军.无血清条件下LIF对小鼠胚胎干细胞增殖及多能性的影响[J].浙江理工大学学报,2011,28(1): 96-100.
[11] Li Z, Fei T, Zhang J, et al.BMP4 Signaling Acts via dual-specificity phosphatase 9 to control ERK activity in mouse embryonic stem cells.Cell Stem Cell. 2012;10(2):171-182.
[12] Angeloni C, Motori E, Fabbri D, et al. H2O2 preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation.Am J Physiol Heart Circ Physiol. 2011; 300(6):H2196-2205.
[13] Mo L, Yang C, Gu M,et al.PI3K/Akt signaling pathway-induced heme oxygenase-1 upregulation mediates the adaptive cytoprotection of hydrogen peroxide preconditioning against oxidative injury in PC12 cells.Int J Mol Med. 2012;30(2): 314-320.
[14] 尉新华,范慧敏,李铁岩,等.小鼠心肌梗死模型的建立和无创评价方法[J].同济大学学报:医学版,2011,32(5):20-22.
[15] Mannheim D, Herrmann J, Bonetti PO,et al.Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. osclerosis. 2011;216(2):283-291.
[16] Nabel EG, Braunwald E.A tale of coronary artery disease and myocardial infarction.N Engl J Med. 2012;366(1):54-63.
[17] Nasef A, Ashammakhi N, Fouillard L.Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med. 2008;3(4):531-546.
[18] llard VL.Stem cells for heart failure in the aging heart.Heart Fail Rev. 2010;15(5):447-456.
[19] Wen J, Zhang JQ, Huang W,et al.SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease.Am J Cardiovasc Dis. 2012;2(1):20-28.
[20] 邹松平,王宇,李春雨,等. 骨髓间充质干细胞旁分泌对急性心肌梗死心肌的保护作用[J].中国组织工程研究,2014,18(23): 3653-3659.
[21] 王欢,邓丽群,王亚利,等. 骨髓间充质干细胞通过旁分泌作用治疗大鼠心肌梗死[J].中华移植杂志:电子版,2013,7(2):94-98.
[22] 杨德忠,王伟,王微,等. 旁分泌机制在脂肪间充质干细胞移植治疗心肌梗死中的作用[J].第三军医大学学报,2013,35(9): 874-879.
[23] 计流,徐夏,王家镜,等.间充质干细胞通过旁分泌效应激活心脏干细胞迁移[J].湖北医药学院学报,2012,31(4):277-284.
[24] 裴志勇,赵玉生.干细胞移植改善心功能的旁分泌机制及治疗策略[J].中华心血管病杂志,2010,38(4):380-384.
[25] 马金萍,王林.骨髓间充质干细胞旁分泌改善心室重塑的作用[J].天津医药,2010,38(10):922-924.
[26] Fedak PW.Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart.Semin Thorac Cardiovasc Surg. 2008;20(2):87-93.
[27] Herrmann JL, Abarbanell AM, Weil BR,et al.Optimizing stem cell function for the treatment of ischemic heart disease.J Surg Res. 2011;166(1):138-145.
[28] Herrmann JL, Weil BR, Abarbanell AM,et al.IL-6 and TGF-α costimulate mesenchymal stem cell vascular endothelial growth factor production by ERK-, JNK-, and PI3K-mediated mechanisms.Shock. 2011;35(5):512-516.
[29] Sanders RD, Sun P, Patel S,et al.Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain.Acta Anaesthesiol Scand. 2010;54(6):710-716.
[30] 郭柏铭,李聪,唐超,等.过氧化氢诱导BMSCs氧化衰老模型的建立及其对相关基因p16、p21、p53表达的影响[J].广州中医药大学学报, 2014,31(4):617-621.
[31] 李丹,徐予,高传玉,等.氧化应激预处理的适应性保护作用[J].临床心血管病杂志,2013,29(12):948-951.
[32] Luo Y, Wang Y, Poynter JA,et al.Pretreating mesenchymal stem cells with interleukin-1β and transforming growth factor-β synergistically increases vascular endothelial growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery. 2012;151(3):353-363.
[33] 姚玲玲,王家宁,黄永章,等.PEP-1-CAT融合蛋白预处理对过氧化氢诱导的内皮细胞氧化应激损伤的保护作用[J].中华心血管病杂志,2006,34(10):932-938.
[34] Zweier JL, Flaherty JT, Weisfeldt ML.Direct measurement of free radical generation following reperfusion of ischemic myocardium.Proc Natl Acad Sci U S A. 1987;84(5): 1404-1407.
[35] Müller BA, Dhalla NS.Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemic-reperfused heart.Curr Cardiol Rev. 2010;6(4): 255-264.
[36] Rosová I, Dao M, Capoccia B,et al.Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.Stem Cells. 2008;26(8):2173-2182.
[37] Brocheriou V, Hagège AA, Oubenaïssa A,et al.Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury.J Gene Med. 2000;2(5):326-333.
[38] Tang XQ, Feng JQ, Chen J,et al.Protection of oxidative preconditioning against apoptosis induced by H2O2 in PC12 cells: mechanisms via MMP, ROS, and Bcl-2.Brain Res. 2005; 1057(1-2):57-64.
[39] Angeloni C, Motori E, Fabbri D,et al.H2O2 preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation.Am J Physiol Heart Circ Physiol. 2011; 300(6):H2196-2205. |